BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spiller R, Pélerin F, Cayzeele Decherf A, Maudet C, Housez B, Cazaubiel M, Jüsten P. Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterol J. 2016;4:353-362. [PMID: 27403301 DOI: 10.1177/2050640615602571] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Li R, Chen F, He X, Feng Y, Pei Q, Wang D, Liu X, Liu J, Hou X, Bai T. Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis. Front Med (Lausanne) 2022;9:1018713. [PMID: 36606047 DOI: 10.3389/fmed.2022.1018713] [Reference Citation Analysis]
2 Liu A, Gao W, Zhu Y, Hou X, Chu H. Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome. Toxins 2022;14:596. [DOI: 10.3390/toxins14090596] [Reference Citation Analysis]
3 Shang X, E FF, Guo KL, Li YF, Zhao HL, Wang Y, Chen N, Nian T, Yang CQ, Yang KH, Li XX. Effectiveness and Safety of Probiotics for Patients with Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials. Nutrients 2022;14:2482. [PMID: 35745212 DOI: 10.3390/nu14122482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522 [DOI: 10.3748/wjg.v28.i22.2509] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhang T, Zhang C, Zhang J, Sun F, Duan L. Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Front Cell Infect Microbiol 2022;12:859967. [DOI: 10.3389/fcimb.2022.859967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Xie CR, Tang B, Shi YZ, Peng WY, Ye K, Tao QF, Yu SG, Zheng H, Chen M. Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis. Front Pharmacol 2022;13:853011. [PMID: 35355730 DOI: 10.3389/fphar.2022.853011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Pogačar MŠ, Mičetić-turk D, Fijan S. Probiotics: current regulatory aspects of probiotics for use in different disease conditions. Probiotics in the Prevention and Management of Human Diseases 2022. [DOI: 10.1016/b978-0-12-823733-5.00021-0] [Reference Citation Analysis]
8 Layer P, Andresen V, Allescher H, Bischoff SC, Claßen M, Elsenbruch S, Freitag M, Frieling T, Gebhard M, Goebel-Stengel M, Häuser W, Holtmann G, Keller J, Kreis ME, Kruis W, Langhorst J, Jansen PL, Madisch A, Mönnikes H, Müller-Lissner S, Niesler B, Pehl C, Pohl D, Raithel M, Röhrig-Herzog G, Schemann M, Schmiedel S, Schwille-Kiuntke J, Storr M, Preiß JC, Andus T, Buderus S, Ehlert U, Engel M, Enninger A, Fischbach W, Gillessen A, Gschossmann J, Gundling F, Haag S, Helwig U, Hollerbach S, Karaus M, Katschinski M, Krammer H, Kuhlbusch-Zicklam R, Matthes H, Menge D, Miehlke S, Posovszky MC, Schaefert R, Schmidt-Choudhury A, Schwandner O, Schweinlin A, Seidl H, Stengel A, Tesarz J, van der Voort I, Voderholzer W, von Boyen G, von Schönfeld J, Wedel T; Collaborators:., in Zusammenarbeit mit:., Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)., Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)., Deutsche Gesellschaft für Ernährungsmedizin (DGEM)., Deutsche Gesellschaft für Geriatrie (DGG)., Deutsche Gesellschaft für Innere Medizin (DGIM)., Deutsche Gesellschaft für Naturheilkunde (DGNHK)., Deutsche Gesellschaft für Pathologie und Bundesverband deutscher Pathologen e. V. (DGP/BDP)., Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM)., Deutsche Gesellschaft für Verhaltensmedizin und Verhaltensmodifikation (DGVM)., Deutsche Schmerzgesellschaft e. V., Deutsches Kollegium für Psychosomatische Medizin (DKPM), Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG)., Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)., Deutschen Gesellschaft für Kinder- und Jugendmedizin (DGKJ)., Swiss Society of Neurogastroenterology and Motility (SwissNGM)., Informationsforum für Patient:innen mit Magen-Darm-Erkrankungen (MAGDA). Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM) – Juni 2021 – AWMF-Registriernummer: 021/016. Z Gastroenterol 2021;59:1323-415. [PMID: 34891206 DOI: 10.1055/a-1591-4794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Xu X, Chen R, Zhan G, Wang D, Tan X, Xu H. Enterochromaffin Cells: Sentinels to Gut Microbiota in Hyperalgesia? Front Cell Infect Microbiol 2021;11:760076. [PMID: 34722345 DOI: 10.3389/fcimb.2021.760076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine 2021;41:101154. [PMID: 34712929 DOI: 10.1016/j.eclinm.2021.101154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
11 Benjak Horvat I, Gobin I, Kresović A, Hauser G. How can probiotic improve irritable bowel syndrome symptoms? World J Gastrointest Surg 2021; 13(9): 923-940 [PMID: 34621470 DOI: 10.4240/wjgs.v13.i9.923] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Singh P, Lembo A. Emerging Role of the Gut Microbiome in Irritable Bowel Syndrome. Gastroenterol Clin North Am 2021;50:523-45. [PMID: 34304786 DOI: 10.1016/j.gtc.2021.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chlebicz-Wójcik A, Śliżewska K. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules 2021;11:1154. [PMID: 34439821 DOI: 10.3390/biom11081154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Koumbi L, Giouleme O, Vassilopoulou E. Non-Celiac Gluten Sensitivity and Irritable Bowel Disease: Looking for the Culprits. Curr Dev Nutr 2020;4:nzaa176. [PMID: 33442571 DOI: 10.1093/cdn/nzaa176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17-44. [PMID: 33315591 DOI: 10.14309/ajg.0000000000001036] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 86.0] [Reference Citation Analysis]
16 Dai YK, Wu YB, Li RL, Chen WJ, Tang CZ, Lu LM, Hu L. Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults. World J Gastroenterol 2020; 26(41): 6488-6509 [PMID: 33244207 DOI: 10.3748/wjg.v26.i41.6488] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 . UEG Week 2020 Poster Presentations. United European Gastroenterol J 2020;8:144-887. [PMID: 33043826 DOI: 10.1177/2050640620927345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Naveed M, Zhou QG, Xu C, Taleb A, Meng F, Ahmed B, Zhang Y, Fukunaga K, Han F. Gut-brain axis: A matter of concern in neuropsychiatric disorders…! Prog Neuropsychopharmacol Biol Psychiatry 2021;104:110051. [PMID: 32758517 DOI: 10.1016/j.pnpbp.2020.110051] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
19 Preidis GA, Weizman AV, Kashyap PC, Morgan RL. AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology 2020;159:708-738.e4. [PMID: 32531292 DOI: 10.1053/j.gastro.2020.05.060] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
20 Di Vito M, Bellardi MG, Sanguinetti M, Mondello F, Girolamo A, Barbanti L, Garzoli S, Sabatino M, Ragno R, Vitali A, Palucci I, Posteraro B, Gasbarrini A, Prati GM, Aragona G, Mattarelli P, Bugli F. Potent In Vitro Activity of Citrus aurantium Essential Oil and Vitis vinifera Hydrolate Against Gut Yeast Isolates from Irritable Bowel Syndrome Patients-The Right Mix for Potential Therapeutic Use. Nutrients 2020;12:E1329. [PMID: 32392768 DOI: 10.3390/nu12051329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
21 Gaziano R, Sabbatini S, Roselletti E, Perito S, Monari C. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Front Microbiol 2020;11:718. [PMID: 32373104 DOI: 10.3389/fmicb.2020.00718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
22 Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.Front Pharmacol. 2020;11:332. [PMID: 32317962 DOI: 10.3389/fphar.2020.00332] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
23 Asha MZ, Khalil SFH. Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis. Sultan Qaboos Univ Med J 2020;20:e13-24. [PMID: 32190365 DOI: 10.18295/squmj.2020.20.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
24 Gao X, Liu J, Li L, Liu W, Sun M. A Brief Review of Nutraceutical Ingredients in Gastrointestinal Disorders: Evidence and Suggestions. Int J Mol Sci 2020;21:E1822. [PMID: 32155799 DOI: 10.3390/ijms21051822] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
25 Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, Hungin APS, Layer P, Mendive JM, Pfeifer J, Rogler G, Scott SM, Simrén M, Whorwell P; Functional Constipation Guidelines Working Group. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterol Motil 2020;32:e13762. [PMID: 31756783 DOI: 10.1111/nmo.13762] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 21.3] [Reference Citation Analysis]
26 Jana T, Acker BW, Cash BD. Probiotics and prebiotics, including fibers and medicinal foods. Clinical and Basic Neurogastroenterology and Motility 2020. [DOI: 10.1016/b978-0-12-813037-7.00042-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci 2020;36:160-70. [PMID: 31782606 DOI: 10.1002/kjm2.12154] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
28 Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth 2019;123:637-54. [PMID: 31551115 DOI: 10.1016/j.bja.2019.07.026] [Cited by in Crossref: 101] [Cited by in F6Publishing: 111] [Article Influence: 25.3] [Reference Citation Analysis]
29 Moayyedi P, Andrews CN, MacQueen G, Korownyk C, Marsiglio M, Graff L, Kvern B, Lazarescu A, Liu L, Paterson WG, Sidani S, Vanner S. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol 2019;2:6-29. [PMID: 31294724 DOI: 10.1093/jcag/gwy071] [Cited by in Crossref: 57] [Cited by in F6Publishing: 66] [Article Influence: 14.3] [Reference Citation Analysis]
30 Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol 2018;13:259-88. [PMID: 30581501 DOI: 10.5114/pg.2018.78343] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
31 Joseph JM, Law C. Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes. Neurosci Biobehav Rev 2019;99:160-97. [PMID: 30471308 DOI: 10.1016/j.neubiorev.2018.11.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther 2018;48:1044-60. [PMID: 30294792 DOI: 10.1111/apt.15001] [Cited by in Crossref: 251] [Cited by in F6Publishing: 275] [Article Influence: 50.2] [Reference Citation Analysis]
33 Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, Quigley EMM; ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol 2018;113:1-18. [PMID: 29950604 DOI: 10.1038/s41395-018-0084-x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 192] [Article Influence: 39.8] [Reference Citation Analysis]
34 Ringot-Destrez B, D'Alessandro Z, Lacroix JM, Mercier-Bonin M, Léonard R, Robbe-Masselot C. A Sensitive and Rapid Method to Determin the Adhesion Capacity of Probiotics and Pathogenic Microorganisms to Human Gastrointestinal Mucins. Microorganisms 2018;6:E49. [PMID: 29844291 DOI: 10.3390/microorganisms6020049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
35 McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2018;5:124. [PMID: 29868585 DOI: 10.3389/fmed.2018.00124] [Cited by in Crossref: 184] [Cited by in F6Publishing: 195] [Article Influence: 36.8] [Reference Citation Analysis]
36 Hungin APS, Mitchell CR, Whorwell P, Mulligan C, Cole O, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Seifert B, Wensaas KA, Winchester C, de Wit N; European Society for Primary Care Gastroenterology. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. Aliment Pharmacol Ther 2018;47:1054-70. [PMID: 29460487 DOI: 10.1111/apt.14539] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 15.4] [Reference Citation Analysis]
37 Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Sci Rep. 2018;8:2964. [PMID: 29445178 DOI: 10.1038/s41598-018-21241-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
38 Gabrielli E, Pericolini E, Ballet N, Roselletti E, Sabbatini S, Mosci P, Decherf AC, Pélerin F, Perito S, Jüsten P, Vecchiarelli A. Saccharomyces cerevisiae-based probiotic as novel anti-fungal and anti-inflammatory agent for therapy of vaginal candidiasis. Benef Microbes 2018;9:219-30. [PMID: 29380641 DOI: 10.3920/BM2017.0099] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
39 Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut 2017;66:966-74. [PMID: 28232472 DOI: 10.1136/gutjnl-2016-313425] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 13.8] [Reference Citation Analysis]
40 Cayzeele-Decherf A, Pélerin F, Leuillet S, Douillard B, Housez B, Cazaubiel M, Jacobson GK, Jüsten P, Desreumaux P. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol 2017; 23(2): 336-344 [PMID: 28127207 DOI: 10.3748/wjg.v23.i2.336] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
41 Pearson JS, Whorwell PJ. Progress with treating the microbial dysbiosis associated with irritable bowel syndrome. Curr Opin Gastroenterol 2017;33:21-5. [PMID: 28134688 DOI: 10.1097/MOG.0000000000000328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Mokha JS, Hyams JS. Irritable Bowel Syndrome. Pediatric Neurogastroenterology 2017. [DOI: 10.1007/978-3-319-43268-7_37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 West C, Stanisz AM, Wong A, Kunze WA. Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility. World J Gastroenterol 2016; 22(48): 10532-10544 [PMID: 28082805 DOI: 10.3748/wjg.v22.i48.10532] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
44 Pélerin F, Desreumaux P. Probiotic Yeast Therapy for Irritable Bowel Syndrome. J Neurogastroenterol Motil 2016;22:542. [PMID: 27354036 DOI: 10.5056/jnm16075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]